US FDA proposes new postmarket reporting rules for combination products
This article was originally published in RAJ Devices
The US Food and Drug Administration, responding to concerns over the lack of specific postmarketing safety reporting requirements for combination products, has issued a much-awaited proposed rule to address the issue1.
You may also be interested in...
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.
The UK scheme allows patients with early access to promising new unlicensed medicines when there is a clear unmet medical need.